10-Year study tracks safety of weekly growth hormone shot in kids

NCT ID NCT06709040

ENROLLING_BY_INVITATION Knowledge-focused Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Apr 11, 2026 · Last updated May 01, 2026 · Updated 1 time

Summary

This study follows 500 children with growth hormone deficiency who are already taking somapacitan (a weekly injection) to see how safe it is over the long term. Researchers will track side effects, medication errors, and whether any children develop new health issues like cancer or type 2 diabetes. The study lasts up to 10 years and does not involve any new treatments—just observation of routine care.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • University of Glasgow

    Glasgow, Scotland, United Kingdom

Conditions

Explore the condition pages connected to this study.